August 12, 2016 (THE HILL) -- Sixty-five years ago our distant fascination with the moon was upended, as President John F. Kennedy challenged our country to put a man on the moon by the end of the 60s. The 1961 proclamation by President Kennedy came to be known as a “moonshot,” and the source of great national pride and inspiration as Neil Armstrong first-touched the surface of the moon in July of 1969. . .
August 05, 2016 (HUFFINGTON POST) -- The day the Twin Towers came down I was working with the New York City Police Department as a Lieutenant. As the call came through about planes crashing into the World Trade Towers, I, like so many other first responders, hurried to the scene . . .
NEW YORK, July 27, 2016 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (OTC QB:TYMI), a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications, announced that its abstract "Preclinical Animal Data of the SM-88 Tyrosine Isomer” has been accepted for poster presentation (display) during the European Society for Medical Oncology (ESMO) 2016 Congress . . .
NEW YORK, June 13, 2016 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (OTCQB:TYMI) (“Tyme”), a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications, announced that it has begun recruiting for a Phase 1b/2 clinical trial, using its proprietary compound, SM-88, to treat prostate cancer.
NEW YORK, June 06, 2016 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (OTCQB:TYMI), a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications, announced that its Chief Medical Officer (CMO), Dr. Giuseppe Del Priore joined an elite group of national and international experts to discuss cancer-related topics at the American College of Obstetricians and Gynecologists (ACOG) Annual Meeting in Washington, DC.
NEW YORK, June 01, 2016 (GLOBE NEWSWIRE) -- According to Tyme Technologies, Inc. (OTCQB:TYMI), a clinical-stage pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics . . .
NEW YORK--(BUSINESS WIRE)--Tyme Technologies, Inc. (OTC QB: TYMI), a research and development company focused on developing drug candidates for the treatment of cancer in humans and operating through its wholly-owned subsidiary Tyme Inc., today reported financial results for the quarter ended September 30, 2015. The Company also provided updated financial guidance for 2015.
Tyme Technologies, Inc. (Tyme, Inc.) (OTC QB:TYMI), a research and development company focused on developing first-in-class oncology drug candidates, has submitted a Phase 2 Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for SM-88, a drug candidate with a unique metabolic approach that has demonstrated initial efficacy and low toxicity in the treatment of multiple types of cancers . . .